
Opinion|Videos|January 29, 2025
Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System
Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Could you discuss the key outcomes from the ARCHWAY trial for PDS?
- The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
2
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
3
Ocular Therapeutix randomizes first patient in HELIOS-3
4
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
5

















































.png)


